BioCryst Pharmaceuticals BCRX Peramivir — Total trade receivables

Similar metrics at other companies

CHDNTrade receivables — Accounts receivable

$58M+18.1%

NGSRentals — Trade accounts receivable

$19.87M+58.6%

HNSTTrade Agreements — Trade agreements asset

$100K—

CSVCemetery — Trade and financed receivables

$33.66M+28.0%

NGSSales and aftermarket services — Trade accounts receivable

$2.55M+46.9%

NTRSTrust Fees Receivable, net — Total Client Receivables

$1.01B+4.0%

FAQ

What is BioCryst Pharmaceuticals's peramivir — total trade receivables?

BioCryst Pharmaceuticals (BCRX) reported peramivir — total trade receivables of $110K in Q2 2026.

How has BioCryst Pharmaceuticals's peramivir — total trade receivables changed year-over-year?

BioCryst Pharmaceuticals's peramivir — total trade receivables decreased by 71.1% year-over-year, from $381K to $110K.

What does peramivir — total trade receivables mean?

This metric represents the total outstanding balance owed to the company by customers for Peramivir product sales that have been invoiced but not yet collected. It serves as a key indicator of the company's credit risk exposure and the efficiency of its accounts receivable collection process for this specific therapeutic product. Monitoring this balance helps investors assess the liquidity generated from product sales and the potential for future cash inflows.